Back

Enhanced cardiac mitochondrial biogenesis by nitro-oleic acid remedies diastolic dysfunction in a mouse model of heart failure with preserved ejection fraction

Mueller, M.; Schubert, T.; Welke, C.; Schulz, T. J.; Patschkowski, T.; Maske, T.; Lengenfelder, L. A.; Landwehrjohann, L.; Donhauser, E.; Vogt, E. T.; Stratmann, B.; Hense, J.; Luedtke, S.; Duefer, M.; Tolstik, E.; Dierks, J.; Hormann, F.-L.; Heiles, S.; Lorenz, K.; Reil, J.-C.; Schopfer, F. J.; Freeman, B. A.; Rudolph, V.; Schlomann, U.; Klinke, A.

2024-02-22 pathology
10.1101/2024.02.20.581137 bioRxiv
Show abstract

Prevalence of heart failure with preserved ejection fraction (HFpEF) is increasing, while treatment options are inadequate. Hypertension and obesity-related metabolic dysfunctions contribute to HFpEF progression. Nitro-oleic acid (NO2-OA) impacts metabolic processes by improving glucose tolerance and adipocyte function. In this study, 4 week treatment with NO2-OA ameliorated diastolic dysfunction in a HFpEF mouse model induced by high-fat diet and inhibition of the endothelial nitric oxide synthase. A proteomic analysis of left ventricular tissue revealed, that one third of the identified proteins, mostly mitochondrial proteins, were upregulated in hearts of NO2-OA-treated HFpEF mice compared to controls and vehicle-treated HFpEF mice, which was confirmed by immunoblot. Activation of the 5-adenosine-monophosphate-activated-protein-kinase (AMPK) signaling pathway mediated an enhancement of mitochondrial biogenesis in hearts of NO2-OA-treated HFpEF mice. In cardiomyocytes under metabolic stress, NO2-OA increased mitochondrial protein level accompanied by enhanced oxidative phosphorylation. In conclusion, targeting mitochondrial integrity in HFpEF leads to improved diastolic function.

Matching journals

The top 11 journals account for 50% of the predicted probability mass.

1
Journal of the American Heart Association
119 papers in training set
Top 0.8%
8.3%
2
PLOS ONE
4510 papers in training set
Top 27%
6.4%
3
International Journal of Molecular Sciences
453 papers in training set
Top 0.7%
6.4%
4
Frontiers in Cardiovascular Medicine
49 papers in training set
Top 0.7%
4.9%
5
BMC Cardiovascular Disorders
14 papers in training set
Top 0.3%
4.4%
6
Antioxidants
25 papers in training set
Top 0.1%
4.4%
7
Pharmacological Research
15 papers in training set
Top 0.1%
3.7%
8
Free Radical Biology and Medicine
33 papers in training set
Top 0.1%
3.6%
9
American Journal of Physiology-Heart and Circulatory Physiology
32 papers in training set
Top 0.3%
3.6%
10
Life Sciences
25 papers in training set
Top 0.2%
3.6%
11
Cells
232 papers in training set
Top 0.8%
3.3%
50% of probability mass above
12
Scientific Reports
3102 papers in training set
Top 43%
2.9%
13
Journal of Cellular and Molecular Medicine
18 papers in training set
Top 0.2%
2.8%
14
Journal of Cellular Physiology
21 papers in training set
Top 0.1%
2.8%
15
Circulation: Heart Failure
14 papers in training set
Top 0.2%
2.1%
16
Frontiers in Pharmacology
100 papers in training set
Top 2%
1.9%
17
Arteriosclerosis, Thrombosis, and Vascular Biology
65 papers in training set
Top 1%
1.7%
18
Gene
41 papers in training set
Top 0.9%
1.7%
19
Atherosclerosis
29 papers in training set
Top 0.8%
1.5%
20
Frontiers in Endocrinology
53 papers in training set
Top 1%
1.2%
21
Critical Care
14 papers in training set
Top 0.4%
1.2%
22
Metabolism
14 papers in training set
Top 0.3%
1.1%
23
Biomedicine & Pharmacotherapy
43 papers in training set
Top 0.7%
1.1%
24
eLife
5422 papers in training set
Top 53%
0.9%
25
Cardiovascular Research
33 papers in training set
Top 0.8%
0.9%
26
Bioscience Reports
25 papers in training set
Top 1%
0.8%
27
European Journal of Pharmacology
11 papers in training set
Top 0.4%
0.8%
28
British Journal of Pharmacology
34 papers in training set
Top 0.5%
0.8%
29
International Immunopharmacology
15 papers in training set
Top 0.5%
0.8%
30
Physiological Reports
35 papers in training set
Top 1%
0.8%